The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: A systematic review and meta-analysis of randomized controlled trials

IF 9.1 2区医学 Q1 PHARMACOLOGY & PHARMACY

Pharmacological research Pub Date : 2024-09-04 DOI:10.1016/j.phrs.2024.107398

{"title":"The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: A systematic review and meta-analysis of randomized controlled trials","authors":"","doi":"10.1016/j.phrs.2024.107398","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Patients with non-alcoholic fatty liver disease (NAFLD) benefit from using synbiotics. However, findings from existing trials remain contentious. Therefore, this meta-analysis evaluated the effects of synbiotics on liver enzymes, blood pressure, inflammation, and lipid profiles in patients with NAFLD.</p></div><div><h3>Methods</h3><p>We searched PubMed, Embase, Cochrane, Scopus, and Web of Science for randomized controlled trials (RCTs) regarding synbiotics supplementation in patients with NAFLD.</p></div><div><h3>Results</h3><p>The meta-analysis revealed that synbiotics supplementation significantly improved liver enzymes (AST, WMD: −9.12 IU/L; 95 % CI: −13.19 to −5.05; ALT, WMD: −8.53 IU/L; 95 % CI: −15.07 to −1.99; GGT, WMD: −10.42 IU/L; 95 % CI: −15.19 to −5.65), lipid profile (TC, WMD: −7.74 mg/dL; 95 % CI: −12.56 to −2.92), obesity indices (body weight, WMD: −1.95 kg; 95 % CI: −3.69 to −0.22; WC, WMD: −1.40 cm; 95 % CI: −2.71 to −0.10), systolic blood pressure (SBP, WMD: −6.00 mmHg; 95 % CI: −11.52 to −0.49), and inflammatory markers (CRP, WMD: −0.69 mg/L; 95 % CI: −1.17 to −0.21; TNF-α, WMD: −14.01 pg/mL; 95 % CI: −21.81 to −6.20).</p></div><div><h3>Conclusion</h3><p>Overall, supplementation with synbiotics positively improved liver enzymes, obesity indices, and inflammatory cytokines in patients with NAFLD.</p></div>","PeriodicalId":19918,"journal":{"name":"Pharmacological research","volume":null,"pages":null},"PeriodicalIF":9.1000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1043661824003438/pdfft?md5=7db5b6e2ec5482dabb819ad6a6d0a95a&pid=1-s2.0-S1043661824003438-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043661824003438","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Patients with non-alcoholic fatty liver disease (NAFLD) benefit from using synbiotics. However, findings from existing trials remain contentious. Therefore, this meta-analysis evaluated the effects of synbiotics on liver enzymes, blood pressure, inflammation, and lipid profiles in patients with NAFLD.

Methods

We searched PubMed, Embase, Cochrane, Scopus, and Web of Science for randomized controlled trials (RCTs) regarding synbiotics supplementation in patients with NAFLD.

Results

The meta-analysis revealed that synbiotics supplementation significantly improved liver enzymes (AST, WMD: −9.12 IU/L; 95 % CI: −13.19 to −5.05; ALT, WMD: −8.53 IU/L; 95 % CI: −15.07 to −1.99; GGT, WMD: −10.42 IU/L; 95 % CI: −15.19 to −5.65), lipid profile (TC, WMD: −7.74 mg/dL; 95 % CI: −12.56 to −2.92), obesity indices (body weight, WMD: −1.95 kg; 95 % CI: −3.69 to −0.22; WC, WMD: −1.40 cm; 95 % CI: −2.71 to −0.10), systolic blood pressure (SBP, WMD: −6.00 mmHg; 95 % CI: −11.52 to −0.49), and inflammatory markers (CRP, WMD: −0.69 mg/L; 95 % CI: −1.17 to −0.21; TNF-α, WMD: −14.01 pg/mL; 95 % CI: −21.81 to −6.20).

Conclusion

Overall, supplementation with synbiotics positively improved liver enzymes, obesity indices, and inflammatory cytokines in patients with NAFLD.

查看原文本刊更多论文

合生元对非酒精性脂肪肝患者肝酶、肥胖指数、血压、血脂和炎症的影响：随机对照试验的系统回顾和荟萃分析。

背景：非酒精性脂肪肝（NAFLD）患者可从合生元中获益。然而，现有试验结果仍存在争议。因此，本荟萃分析评估了合生元对非酒精性脂肪肝患者肝酶、血压、炎症和血脂的影响：我们在PubMed、Embase、Cochrane、Scopus和Web of Science上搜索了有关非酒精性脂肪肝患者补充益生菌的随机对照试验（RCT）：92）、肥胖指数（体重，WMD：-1.95kg；95% CI：-3.69 至 -0.22；WC，WMD：-1.40cm；95% CI：-2.71 至 -0.10）、收缩压（SBP，WMD：-6.00mmHg；95% CI：-11.52 至 -0.49）和炎症指标（CRP，WMD：-0.69mg/L；95% CI：-1.17 至 -0.21；TNF-α，WMD：-14.01pg/mL；95% CI：-21.81 至 -6.20）：总之，补充合生元能积极改善非酒精性脂肪肝患者的肝酶、肥胖指数和炎症细胞因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacological research 医学-药学

CiteScore

18.70

自引率

3.20%

发文量

491

审稿时长

8 days

期刊介绍： Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.

文献相关原料

公司名称	产品信息	采购帮参考价格